Log in

Helius Medical Technologies Stock Price, News & Analysis (OTCMKTS:HSDT)

+0.06 (+3.73 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: $1.67
50-Day Range
MA: $1.76
52-Week Range
Now: $1.67
Volume12,866 shs
Average Volume113,893 shs
Market Capitalization$43.26 million
P/E RatioN/A
Dividend YieldN/A
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:HSDT



Sales & Book Value

Annual SalesN/A



Market Cap$43.26 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive HSDT News and Ratings via Email

Sign-up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.

Helius Medical Technologies (OTCMKTS:HSDT) Frequently Asked Questions

What is Helius Medical Technologies' stock symbol?

Helius Medical Technologies trades on the OTCMKTS under the ticker symbol "HSDT."

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies Inc (OTCMKTS:HSDT) posted its earnings results on Thursday, August, 8th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The business had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.40 million. View Helius Medical Technologies' Earnings History.

When is Helius Medical Technologies' next earnings date?

Helius Medical Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Helius Medical Technologies.

What guidance has Helius Medical Technologies issued on next quarter's earnings?

Helius Medical Technologies issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.6-2 million.

What price target have analysts set for HSDT?

2 Wall Street analysts have issued 1 year target prices for Helius Medical Technologies' stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate Helius Medical Technologies' stock price to reach $12.00 in the next year. This suggests a possible upside of 618.6% from the stock's current price. View Analyst Price Targets for Helius Medical Technologies.

What is the consensus analysts' recommendation for Helius Medical Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Helius Medical Technologies.

Has Helius Medical Technologies been receiving favorable news coverage?

News coverage about HSDT stock has trended somewhat positive on Saturday, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Helius Medical Technologies earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Helius Medical Technologies.

Who are some of Helius Medical Technologies' key competitors?

What other stocks do shareholders of Helius Medical Technologies own?

Who are Helius Medical Technologies' key executives?

Helius Medical Technologies' management team includes the folowing people:
  • Philippe Deschamps, President, Chief Executive Officer, Director
  • Joyce N. LaViscount, Chief Financial Officer, Chief Operating Officer
  • Brian Bapty, Vice President, Strategy and Business Development
  • Jonathan Sackier, Chief Medical Officer
  • Dane Andreeff, Director
  • Huaizheng Peng, Director
  • Mitch Eugene Tyler, Director
  • Thomas E. Griffin, Independent Director
  • Edward M. Straw, Independent Director

How do I buy shares of Helius Medical Technologies?

Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Helius Medical Technologies' stock price today?

One share of HSDT stock can currently be purchased for approximately $1.67.

How big of a company is Helius Medical Technologies?

Helius Medical Technologies has a market capitalization of $43.26 million. View Additional Information About Helius Medical Technologies.

What is Helius Medical Technologies' official website?

The official website for Helius Medical Technologies is http://www.heliusmedical.com/.

How can I contact Helius Medical Technologies?

Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at 215-944-6100 or via email at [email protected]

MarketBeat Community Rating for Helius Medical Technologies (OTCMKTS HSDT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Helius Medical Technologies and other stocks. Vote "Outperform" if you believe HSDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: Quantitative Easing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel